# Spero Therapeutics Inc. (SPRO)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $150M  
**Price:** $2.54 (-1.17%)

> Spero Therapeutics Inc. is a biopharmaceutical company focused on developing novel treatments for infectious diseases, particularly those caused by antibiotic-resistant bacteria. The primary function of Spero Therapeutics is to address the growing global challenge of bacterial infections that are difficult to treat with existing antibiotics. The company’s pipeline includes innovative therapies targeted at multi-drug resistant bacterial infections, which are essential in hospital and healthcare environments. Spero employs cutting-edge scientific research and development techniques to create oral and intravenous (IV) treatment options that provide effective alternatives for patients and physicians. Headquartered in Cambridge, Massachusetts, Spero Therapeutics plays a critical role in the pharmaceutical industry by advancing the development of new antibiotic therapies, thus contributing to public health and safety. Its work is particularly significant in the context of increasing concerns about antibiotic resistance, which poses a severe threat to global health systems.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $13M | — | $6M | $9M | — |
| 2024 | $371,000 | — | -$73M | -$69M | — |
| 2023 | $933,000 | — | $21M | $23M | — |
| 2022 | $3M | — | -$42M | — | — |
| 2021 | $3M | — | -$88M | -$90M | — |
| 2020 | $258,000 | — | -$79M | -$78M | — |
| 2019 | $5M | — | -$63M | -$61M | — |
| 2018 | $4M | — | -$43M | -$42M | — |
| 2017 | $2M | — | -$42M | -$39M | — |
| 2016 | $335,000 | — | -$33M | -$25M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $69M | $10M | $59M | $40M | — |
| 2024 | $111M | $64M | $46M | $53M | — |
| 2023 | $182M | $75M | $107M | $76M | — |
| 2022 | $125M | $49M | $76M | $109M | — |
| 2021 | $171M | $83M | $88M | $113M | — |
| 2020 | $153M | $21M | $132M | $85M | — |
| 2019 | $106M | $32M | $75M | $30M | — |
| 2018 | $129M | $13M | $116M | $34M | — |
| 2017 | $93M | $9M | $85M | $87M | — |
| 2016 | $14M | $7M | -$45M | $10M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$13M | — | — |
| 2024 | -$23M | — | — |
| 2023 | -$33M | — | — |
| 2022 | -$8M | — | — |
| 2021 | -$64M | — | — |
| 2020 | -$86M | $157,000 | -$86M |
| 2019 | -$50M | $314,000 | -$50M |
| 2018 | -$40M | $2M | -$42M |
| 2017 | -$39M | $27,000 | -$39M |
| 2016 | -$29M | $830,000 | -$30M |

Source: [CompaniesByCap](https://companiesbycap.com/company/SPRO)